Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Oncology

Living with Carcinoid Syndrome: Daily Management & Surveillance

At a Glance

Daily carcinoid syndrome care is individualized: track food and stress triggers, protect nutrition, report oily stools or worsening symptoms, and follow a personalized schedule for scans, hormone tests, and heart checks. Counseling and palliative support can help preserve quality of life.

Living with Carcinoid Syndrome requires more than just medical treatment; it involves a daily commitment to symptom tracking, nutritional awareness, and a structured schedule of long-term monitoring [1][2]. Because this may require long-term management, especially when the NET has spread, the goal of daily management is to minimize “flares” and maintain your quality of life while staying ahead of potential complications [3][4].

Navigating Dietary and Lifestyle Triggers

Many patients find that certain foods or behaviors can be associated with a sudden flush or diarrhea episode [5][6]. While triggers are highly individual and not predictable for everyone, commonly reported factors include:

  • Alcohol: Red wine, beer, and spirits are frequent triggers for flushing [6][7].
  • Amine-Rich Foods: Foods that are aged, fermented, or pickled—such as aged cheeses, smoked meats, and sauerkraut—contain high levels of amines that may worsen symptoms [2][8].
  • Large Meals: Overfilling the stomach can sometimes provoke symptoms [2].
  • Stress: Emotional or physical stress is often reported as a precipitating factor [9].

The “Individualized” Approach: Rather than following a strictly restrictive diet that might lead to malnutrition, you should keep a food and symptom diary [5][2]. Only avoid foods that reproducibly cause you to have a flare [5]. Working with a dietitian who has experience in neuroendocrine tumors (NETs) is vital to ensure you are getting enough calories and protein [10][11]. Do not stop nutritious foods or lose weight without a dietitian’s help.

Addressing Nutritional Gaps

Carcinoid Syndrome can lead to specific vitamin and mineral deficiencies that you and your doctor should watch for:

  • Niacin (Vitamin B3) Deficiency: Because the tumor can use your body’s supply of tryptophan to make serotonin, it can leave very little left to make niacin [12][13]. This can lead to pellagra, an uncommon but important condition marked by skin rashes, diarrhea, and confusion [13]. Supplementation should be based on clinical assessment; do not self-start high-dose supplements, as some forms of niacin can worsen flushing [14][12].
  • Fat-Soluble Vitamins: Somatostatin analogs (SSAs) can sometimes interfere with how your body absorbs fats [12][15]. This can lead to deficiencies in vitamins A, D, E, and K [12]. Vitamin D deficiency is particularly common and can affect bone health [15][16].
  • Malabsorption: If your diarrhea is oily, floating, or foul-smelling, it may be caused by Pancreatic Exocrine Insufficiency (PEI) rather than the syndrome itself [17][18]. This is often a side effect of SSA therapy or prior surgeries and can be managed with enzyme replacement pills [17][19].

Your Surveillance Schedule

A rigorous monitoring plan is the best way to ensure your treatment remains effective. Your specific schedule will be “risk-adapted” based on your tumor grade, disease burden, and symptom control; the intervals below are examples, not a rigid prescription [1][20].

Test Example Frequency Why it Matters
Physical Exam & Symptoms Every 3–6 months [21] Tracks daily quality of life and treatment side effects.
5-HIAA (Urine or Blood) Every 3–6 months [1] Monitors the “hormone burden” and risk for heart disease [22].
CT or MRI Scans Every 3–6 months [21] Checks for changes in tumor size or new spots in the liver.
Echocardiogram Every 6–12 months [1] Screens for early signs of valve damage (CHD) [23].
NT-proBNP Blood Test Periodic clinic visits [23] A sensitive “early warning” marker for heart stress [22].

Managing the Psychological Toll

It is normal to experience scanxiety—the intense anxiety that builds up before a scheduled scan—and the emotional weight of living with a condition requiring long-term care [1]. Because symptoms like flushing can be visible to others, they can sometimes cause social withdrawal or embarrassment [6].

A multidisciplinary approach that includes a counselor, a support group, or a palliative care specialist (who focuses on symptom management and quality of life alongside active cancer treatment) can provide essential support [1][4]. You are not just managing a collection of laboratory values; you are managing a life that deserves to be lived as fully as possible [3].

Common questions in this guide

What foods and habits commonly trigger carcinoid syndrome flares?
Triggers vary from person to person, but alcohol, aged or fermented foods, large meals, and emotional or physical stress are commonly reported. Keep a food and symptom diary and avoid only triggers that repeatedly cause symptoms, rather than adopting an unnecessarily restrictive diet.
Why should I keep a food and symptom diary for carcinoid syndrome?
Recording meals, drinks, stress, flushing, and bowel changes can help reveal personal patterns. A dietitian familiar with neuroendocrine tumors can help you avoid reproducible triggers without losing needed calories or protein.
Can carcinoid syndrome cause vitamin deficiencies?
The tumor may use tryptophan to make serotonin, leaving less available for niacin production and, in some people, contributing to pellagra. Somatostatin analog treatment may also reduce fat absorption and lead to low vitamins A, D, E, or K, so testing and supplements should be guided by a clinician.
What do oily, floating, or foul-smelling stools mean?
These stool changes can suggest pancreatic exocrine insufficiency, in which the pancreas does not provide enough digestive enzymes, rather than being caused only by carcinoid syndrome. Somatostatin analog treatment or previous surgery can contribute, and a clinician may recommend evaluation and pancreatic enzyme replacement.
How often should carcinoid syndrome be monitored?
Follow-up is individualized according to tumor grade, disease burden, and symptom control. Example schedules may include an exam, symptom review, 5-HIAA testing, and CT or MRI every 3 to 6 months, with an echocardiogram every 6 to 12 months and NT-proBNP at periodic visits.
How can I cope with scanxiety and the emotional strain of chronic care?
Anxiety before scans and embarrassment about visible flushing are common emotional challenges. A counselor, support group, or palliative care specialist can provide support and help manage symptoms and quality of life alongside active treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have we checked my nutritional status, and should I be evaluated for rare deficiencies like pellagra?
  2. 2.Based on my stool frequency and character, should I be evaluated for pancreatic enzyme insufficiency (PEI) or bile-acid malabsorption?
  3. 3.Given my recent imaging and 5-HIAA levels, what is the appropriate surveillance interval for my next set of scans?
  4. 4.Is my current vitamin D level sufficient, or should I be taking a specific dose to protect my bone health while on SSAs?
  5. 5.Can you refer me to a dietitian who specifically works with neuroendocrine tumor patients to help me identify reproducible food triggers?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers.

    Algeri L, Falkman L, Spada F, et al.

    ESMO open 2024; (9(11)):103959 doi:10.1016/j.esmoop.2024.103959.

    PMID: 39442478
  2. 2

    Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors.

    Artale S, Barzaghi S, Grillo N, et al.

    Nutrition and cancer 2022; (74(1)):2-11 doi:10.1080/01635581.2020.1838572.

    PMID: 33148022
  3. 3

    TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.

    Strosberg J, Joish VN, Giacalone S, et al.

    The oncologist 2019; (24(11)):1446-1452 doi:10.1634/theoncologist.2018-0921.

    PMID: 31189618
  4. 4

    Exploring Carcinoid Syndrome in Neuroendocrine Tumors: Insights from a Multidisciplinary Narrative Review.

    Marasco M, Romano E, Arrivi G, et al.

    Cancers 2024; (16(22)) doi:10.3390/cancers16223831.

    PMID: 39594786
  5. 5

    Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index.

    Shaunfield S, Webster KA, Kaiser K, et al.

    Neuroendocrinology 2021; (111(9)):850-862 doi:10.1159/000511482.

    PMID: 32911478
  6. 6

    Carcinoid syndrome mimicking irritable bowel syndrome: don't fall into the trap.

    Massironi S, Gallo C, Franchina M, et al.

    Expert review of gastroenterology & hepatology 2025; (19(10)):1119-1132 doi:10.1080/17474124.2025.2557245.

    PMID: 40902188
  7. 7

    Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors.

    Eads JR, Reidy-Lagunes D, Soares HP, et al.

    Pancreas 2020; (49(9)):1123-1130 doi:10.1097/MPA.0000000000001658.

    PMID: 32991344
  8. 8

    Optimizing the Management of Carcinoid Syndrome to Reduce the Impact of Diarrhea.

    Randall R, Bennett B, Valone T, Blue K

    Journal of the advanced practitioner in oncology 2019; (10(8)):862-872 doi:10.6004/jadpro.2019.10.8.7.

    PMID: 33425469
  9. 9

    Flushing in (neuro)endocrinology.

    Hannah-Shmouni F, Stratakis CA, Koch CA

    Reviews in endocrine & metabolic disorders 2016; (17(3)):373-380 doi:10.1007/s11154-016-9394-8.

    PMID: 27873108
  10. 10

    Malnutrition Predicts Clinical Outcome in Patients with Neuroendocrine Neoplasia.

    Maasberg S, Knappe-Drzikova B, Vonderbeck D, et al.

    Neuroendocrinology 2017; (104(1)):11-25 doi:10.1159/000442983.

    PMID: 26641457
  11. 11

    Sarcopenia in Patients with Advanced Gastrointestinal Well-Differentiated Neuroendocrine Tumors.

    Romano E, Polici M, Marasco M, et al.

    Nutrients 2024; (16(14)) doi:10.3390/nu16142224.

    PMID: 39064666
  12. 12

    Nutritional Complications and the Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors.

    Laing E, Kiss N, Michael M, Krishnasamy M

    Neuroendocrinology 2020; (110(5)):430-442 doi:10.1159/000503634.

    PMID: 31550712
  13. 13

    Carcinoid Syndrome: A Review.

    Gade AK, Olariu E, Douthit NT

    Cureus 2020; (12(3)):e7186 doi:10.7759/cureus.7186.

    PMID: 32257725
  14. 14

    Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor.

    Bouma G, van Faassen M, Kats-Ugurlu G, et al.

    Neuroendocrinology 2016; (103(5)):489-94 doi:10.1159/000440621.

    PMID: 26335390
  15. 15

    Nutritional and vitamin status in patients with neuroendocrine neoplasms.

    Clement DS, Tesselaar ME, van Leerdam ME, et al.

    World journal of gastroenterology 2019; (25(10)):1171-1184 doi:10.3748/wjg.v25.i10.1171.

    PMID: 30886501
  16. 16

    Fragility fractures in well-differentiated gastroenteropancreatic neuroendocrine tumors: Results from a multicentered retrospective study.

    Brunetti A, Cellini M, Lavezzi E, et al.

    Journal of neuroendocrinology 2025; (37(9)):e70053 doi:10.1111/jne.70053.

    PMID: 40452250
  17. 17

    Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.

    Khan MS, Walter T, Buchanan-Hughes A, et al.

    World journal of gastroenterology 2020; (26(30)):4537-4556 doi:10.3748/wjg.v26.i30.4537.

    PMID: 32874063
  18. 18

    Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.

    Weickert MO, Kaltsas G, Hörsch D, et al.

    Clinical therapeutics 2018; (40(6)):952-962.e2 doi:10.1016/j.clinthera.2018.04.006.

    PMID: 29724499
  19. 19

    Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors.

    Pusceddu S, Rossi RE, Torchio M, et al.

    Journal of clinical medicine 2020; (9(8)) doi:10.3390/jcm9082468.

    PMID: 32752158
  20. 20

    Carcinoid Heart Disease and Decreased Overall Survival among Patients with Neuroendocrine Tumors: A Retrospective Multicenter Latin American Cohort Study.

    Uema D, Alves C, Mesquita M, et al.

    Journal of clinical medicine 2019; (8(3)) doi:10.3390/jcm8030405.

    PMID: 30909590
  21. 21

    Managing end-stage carcinoid heart disease: A case report and literature review.

    Bulj N, Tomasic V, Cigrovski Berkovic M

    World journal of gastrointestinal oncology 2024; (16(3)):1076-1083 doi:10.4251/wjgo.v16.i3.1076.

    PMID: 38577438
  22. 22

    The Value of Repeat 5-HIAA Measurements as a Predictor of Carcinoid Heart Disease: A Prospective 5-Year Follow-Up Study in Patients with Small Intestinal Neuroendocrine Tumors.

    Kostiainen I, Simonen P, Aaltonen K, et al.

    Cancers 2024; (16(23)) doi:10.3390/cancers16233896.

    PMID: 39682084
  23. 23

    Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration.

    Das S, Stockton SS, Hassan SA

    The oncologist 2023; (28(7)):575-583 doi:10.1093/oncolo/oyad126.

    PMID: 37209415

This page provides general information about living with carcinoid syndrome and does not constitute medical advice. Consult your healthcare team before changing your diet, taking supplements, or altering your surveillance schedule.

Get notified when new evidence is published on Carcinoid syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.